RT Journal Article
SR Electronic
T1 Extremely preterm infant admissions within the SafeBoosC-III consortium during the COVID-19 lockdown
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.02.20204578
DO 10.1101/2020.10.02.20204578
A1 Rasmussen, Marie Isabel
A1 Lühr Hansen, Mathias
A1 Pichler, Gerhard
A1 Dempsey, Eugene
A1 Pellicer, Adelina
A1 EL-Khuffash, Afif
A1 Shashidhar, A
A1 Piris-Borregas, Salvador
A1 Alsina, Miguel
A1 Cetinkaya, Merih
A1 Chalak, Lina
A1 Ozkan, Hilal
A1 Baserga, Mariana
A1 Sirc, Jan
A1 Fuchs, Hans
A1 Ergenekon, Ebru
A1 Arruza, Luis
A1 Mathur, Amit
A1 Stocker, Martin
A1 Vaccarello, Olalla Otero
A1 Szczapa, Tomasz
A1 Sarafidis, Kosmas
A1 Krolak-Olejnik, Barbara
A1 Memisoglu, Asli
A1 Reigstad, Hallvard
A1 Rafińska-Ważny, Elżbieta
A1 Hatzidaki, Eleftheria
A1 Peng, Zhang
A1 Gkentzi, Despoina
A1 Viellevoye, Renaud
A1 De Buyst, Julie
A1 Mastretta, Emmanuele
A1 Wang, Ping
A1 Hahn, Gitte Holst
A1 Bender, Lars
A1 Cornette, Luc
A1 Tkaczyk, Jakub
A1 Rio, Ruth del
A1 Fumagalli, Monica
A1 Papathoma, Evangelina
A1 Wilinska, Maria
A1 Naulers, Gunnar
A1 Sadowska-Krawczenko, Iwona
A1 Lecart, Chantal
A1 Couce, María Luz
A1 Fredly, Siv
A1 Heuchan, Anne Marie
A1 Karen, Tanja
A1 Greisen, Gorm
YR 2020
UL http://medrxiv.org/content/early/2020/10/05/2020.10.02.20204578.abstract
AB Objective To evaluate if the number of admitted extremely preterm (EP) infants (born before 28 weeks of gestational age) has changed in the neonatal intensive care units (NICUs) of the SafeBoosC-III consortium during the global lockdown when compared to the corresponding time period in 2019.Design This is a retrospective, observational study. Forty-six out of 79 NICUs (58%) from 17 countries participated. Principal investigators were asked to report the following information: 1) Total number of EP infant admissions to their NICU in the three months where the lockdown restrictions were most rigorous during the first phase of the COVID-19 pandemic, 2) Similar EP infant admissions in the corresponding three months of 2019, 3) the level of local restrictions during the lockdown period and 4) the local impact of the COVID-19 lockdown on the everyday life of a pregnant woman.Results There was no significant difference between the number of EP infant admissions during the three most rigorous lockdown months of the COVID-19 pandemic compared to the corresponding three months in 2019 (n=428 versus n=457 respectively, p=0.33). There were no significant changes within individual geographic regions and no significant association between the level of lockdown restrictions and change in the number of EP infant admissions (p=0.334).Conclusion This larger ad hoc study did not confirm previous studies’ report of a major reduction in the number of extremely preterm births during the first phase of the COVID-19 pandemic.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04527601Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04527601 Funding StatementThe sponsor/coordinating investigator, Professor of Paediatrics Gorm Greisen, is the initiator of the SafeBoosC-III project. He has no financial interest in the results of the trial. The Elsass Foundation, Aage and Johanne Louis-Hansen Foundation, and Svend Andersen Foundation supported the SafeBoosC-III trial through unconditional and unrestricted grants of DKK 2,700,000, DKK 1,000,000 and DKK 1,000,000, respectively. These funding sources had no role in the design of this study and will not have any role during its execution, analysis, interpretation of the data or decision to submit results.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:According to Danish law, ethical permission to conduct this study was not necessary.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on request and will be published on www.safeboosc.eu